<?xml version="1.0" encoding="UTF-8"?>
<p>To investigate whether VGCV is active against Ad6 infection, we infected immunosuppressed hamsters with Ad5 or Ad6. To equalize the pathogenicity of the two viruses, we administered 10-fold less Ad6 than Ad5 (2 × 10
 <sup>11</sup> PFU/kg of Ad5 v. 2 × 10
 <sup>10</sup> PFU/kg of Ad6). VGCV was used at a dose and treatment schedule known to be effective against Ad5 (200 mg/kg b.i.d., starting one day before challenge) [
 <xref rid="B25-viruses-09-00147" ref-type="bibr">25</xref>]. 
</p>
